RNA Formulation Resources

  1. Developing An mRNA-Encoded Antibody Platform To Accelerate Therapies To Clinic 11/20/2024

    In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.

  2. Ready To Amplify Plasmid (pDNA) In Bacteria? 11/14/2023

    Explore how to use and amplify pDNA from the development of recombinant proteins and viral vectors to advanced bio-therapeutics such as mRNA vaccines.

  3. Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing 8/5/2025

    Learn about a continuous manufacturing platform designed to help overcome challenges in domestic pharmaceutical production, including scale-up barriers and production variability.

  4. Nanomedicine Modalities Find Path To Clinic Through Analytics 5/16/2025

    Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.

  5. Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs 4/18/2022

    This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.

  6. CQA Assessment Of LNP-Encapsulated IVT mRNA 4/21/2025

    Learn more about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system.

  7. Turbulent Mixing: Scaling Up Nanoparticle Manufacturing For The Future

    Choosing between turbulent and microfluidic mixing methods in your lipid nanoparticle (LNP) production can have a significant impact when scaling up production.

  8. PEG In LNP Formulations: Addressing Challenges And Seeking Solutions 2/8/2024

    Polyethylene glycol and similar variants have driven innovative research for therapies. However, the continued use of PEG poses significant drawbacks.

  9. Fit-For-Purpose Lipids Can Accelerate, Scale, And Improve RNA-LNP Drugs 6/22/2023

    Emerging biotech companies are investing in novel delivery capabilities to address different modalities' needs and extra-hepatic delivery. Explore steps to accelerate commercial nanomedicine delivery.

  10. Novel Lipid Nanoparticle Delivery Reagent And Manufacturing Workflow 4/18/2022

    We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.